scaav sgrna gfp (Addgene inc)
Addgene inc is a verified supplier 
92
Structured Review
Addgene inc
scaav sgrna gfp
Scaav Sgrna Gfp, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sgrnas/scAAV+GFP+(Plasmid+%2321893)/pmc13022658-113-6-7
Average 92 stars, based on 7 article reviews
Scaav Sgrna Gfp, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sgrnas/scAAV+GFP+(Plasmid+%2321893)/pmc13022658-113-6-7
Average 92 stars, based on 7 article reviews
scaav sgrna gfp - by Bioz Stars,
2026-09
92/100 stars
Images
Related Articles
Transduction:Article Title: eIF4G2-dependent translation restrains pancreatic cancer progression Article Snippet: .. KPC cells were transduced with lentivirus expressing Cas9 and Article Title: KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2 Article Snippet: .. For GFP-depletion assays, cells stably expressing Cas9 from a LentiV-Cas9-blasticidin vector were lentivirally transduced with Expressing:Article Title: eIF4G2-dependent translation restrains pancreatic cancer progression Article Snippet: .. KPC cells were transduced with lentivirus expressing Cas9 and Article Title: KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2 Article Snippet: .. For GFP-depletion assays, cells stably expressing Cas9 from a LentiV-Cas9-blasticidin vector were lentivirally transduced with Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: Goto et al. [ ] , CAL27 , Human kinome CRISPR pooled library (Brunello, RRID: Addgene_75312); Coverage: 650×; MOI: 0.3. , INK128 (10 nM) treatment until ~20 population doublings. Puromycin selection not specified , Treatment-Perturbed (mTOR inhibitor INK128 10 nM) , CDK4/6 signaling , - Identified synthetic lethality between mTOR and CDK4/6 signaling - Combination of INK128 and palbociclib leads to synergistic killing in vitro/in vivo - Mechanism: blocking eIF4G-CCNE1 complex formation. , N/A. .. Qiu et al. [ ] , SCC15 , Human GeCKO v2 CRISPR library (A + B sets, Addgene #1000000049), 122,411 CRISPR:Article Title: A systematic CRISPR screen reveals an NBL1-mediated Jak/Stat3 crosstalk to promote ovarian cancer metastasis Article Snippet: All the mediums were supplemented with 10% fetal bovine serum (BI, China) and 1% penicillin–streptomycin (Invitrogen, China) and maintained in an atmosphere of 5% CO 2 and 95% air at 37 °C. .. The method for the highly metastatic gene screening process using the CRISPR/Cas9 library has been established., Briefly, the procedure was as follows: the GeCKO v2 human sgRNA library (developed by Zhangfeng's lab and obtained from Addgene) contains 122,756 Article Title: CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer Article Snippet: .. We acquired the Toronto Knockout CRISPR (TKOv3) library, which contains 71,090 Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: Qiu et al. [ ] , SCC15 , Human GeCKO v2 CRISPR library (A + B sets, Addgene #1000000049), 122,411 sgRNAs targeting 19,052 genes + 1864 miRNAs; Coverage: 500×; MOI: 0.3 , Puromycin (2 μg/mL × 7 days). Cells exposed to oHSV-1 for 48 h (control) and 72 h (treatment) for positive/negative selection , Treatment-Perturbed (oHSV-1 infection) , SUV39H2 , - Identified SUV39H2 as a host barrier to oHSV-1 - Genetic loss or OTS186935 boosts viral gene expression/replication and T cell infiltration, thereby enhancing anti-tumor efficacy in vitro and in vivo. , N/A. .. Allevato et al. [ ] , CAL33 , Brunello whole-genome CRISPR library (Addgene #73178), 76,441 Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: .. Chai et al. [ ] , ORL48, ORL115, ORL136, ORL150, ORL153, ORL156, ORL166, ORL174, ORL188, ORL195, ORL204, ORL207, ORL214, ORL215 , Human Improved Genome-wide Knockout CRISPR Library v1 (Addgene #67989), 90,709 Article Title: CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer. Article Snippet: .. Construction of TKOv3 Library We acquired the Toronto Knockout CRISPR (TKOv3) library, which contains 71,090 Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: Goto et al. [ ] , CAL27 , Human kinome CRISPR pooled library (Brunello, RRID: Addgene_75312); Coverage: 650×; MOI: 0.3. , INK128 (10 nM) treatment until ~20 population doublings. Puromycin selection not specified , Treatment-Perturbed (mTOR inhibitor INK128 10 nM) , CDK4/6 signaling , - Identified synthetic lethality between mTOR and CDK4/6 signaling - Combination of INK128 and palbociclib leads to synergistic killing in vitro/in vivo - Mechanism: blocking eIF4G-CCNE1 complex formation. , N/A. .. Qiu et al. [ ] , SCC15 , Human GeCKO v2 CRISPR library (A + B sets, Addgene #1000000049), 122,411 Knock-Out:Article Title: CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer Article Snippet: .. We acquired the Toronto Knockout CRISPR (TKOv3) library, which contains 71,090 Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: .. Chai et al. [ ] , ORL48, ORL115, ORL136, ORL150, ORL153, ORL156, ORL166, ORL174, ORL188, ORL195, ORL204, ORL207, ORL214, ORL215 , Human Improved Genome-wide Knockout CRISPR Library v1 (Addgene #67989), 90,709 Article Title: CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer. Article Snippet: .. Construction of TKOv3 Library We acquired the Toronto Knockout CRISPR (TKOv3) library, which contains 71,090 Electroporation:Article Title: CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer Article Snippet: .. We acquired the Toronto Knockout CRISPR (TKOv3) library, which contains 71,090 Article Title: CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer. Article Snippet: .. Construction of TKOv3 Library We acquired the Toronto Knockout CRISPR (TKOv3) library, which contains 71,090 Selection:Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: Qiu et al. [ ] , SCC15 , Human GeCKO v2 CRISPR library (A + B sets, Addgene #1000000049), 122,411 sgRNAs targeting 19,052 genes + 1864 miRNAs; Coverage: 500×; MOI: 0.3 , Puromycin (2 μg/mL × 7 days). Cells exposed to oHSV-1 for 48 h (control) and 72 h (treatment) for positive/negative selection , Treatment-Perturbed (oHSV-1 infection) , SUV39H2 , - Identified SUV39H2 as a host barrier to oHSV-1 - Genetic loss or OTS186935 boosts viral gene expression/replication and T cell infiltration, thereby enhancing anti-tumor efficacy in vitro and in vivo. , N/A. .. Allevato et al. [ ] , CAL33 , Brunello whole-genome CRISPR library (Addgene #73178), 76,441 Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: Goto et al. [ ] , CAL27 , Human kinome CRISPR pooled library (Brunello, RRID: Addgene_75312); Coverage: 650×; MOI: 0.3. , INK128 (10 nM) treatment until ~20 population doublings. Puromycin selection not specified , Treatment-Perturbed (mTOR inhibitor INK128 10 nM) , CDK4/6 signaling , - Identified synthetic lethality between mTOR and CDK4/6 signaling - Combination of INK128 and palbociclib leads to synergistic killing in vitro/in vivo - Mechanism: blocking eIF4G-CCNE1 complex formation. , N/A. .. Qiu et al. [ ] , SCC15 , Human GeCKO v2 CRISPR library (A + B sets, Addgene #1000000049), 122,411 Stable Transfection:Article Title: KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2 Article Snippet: .. For GFP-depletion assays, cells stably expressing Cas9 from a LentiV-Cas9-blasticidin vector were lentivirally transduced with Genome Wide:Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: .. Chai et al. [ ] , ORL48, ORL115, ORL136, ORL150, ORL153, ORL156, ORL166, ORL174, ORL188, ORL195, ORL204, ORL207, ORL214, ORL215 , Human Improved Genome-wide Knockout CRISPR Library v1 (Addgene #67989), 90,709 DNA Extraction:Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: .. Chai et al. [ ] , ORL48, ORL115, ORL136, ORL150, ORL153, ORL156, ORL166, ORL174, ORL188, ORL195, ORL204, ORL207, ORL214, ORL215 , Human Improved Genome-wide Knockout CRISPR Library v1 (Addgene #67989), 90,709 In Vitro:Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: .. Chai et al. [ ] , ORL48, ORL115, ORL136, ORL150, ORL153, ORL156, ORL166, ORL174, ORL188, ORL195, ORL204, ORL207, ORL214, ORL215 , Human Improved Genome-wide Knockout CRISPR Library v1 (Addgene #67989), 90,709 Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: Goto et al. [ ] , CAL27 , Human kinome CRISPR pooled library (Brunello, RRID: Addgene_75312); Coverage: 650×; MOI: 0.3. , INK128 (10 nM) treatment until ~20 population doublings. Puromycin selection not specified , Treatment-Perturbed (mTOR inhibitor INK128 10 nM) , CDK4/6 signaling , - Identified synthetic lethality between mTOR and CDK4/6 signaling - Combination of INK128 and palbociclib leads to synergistic killing in vitro/in vivo - Mechanism: blocking eIF4G-CCNE1 complex formation. , N/A. .. Qiu et al. [ ] , SCC15 , Human GeCKO v2 CRISPR library (A + B sets, Addgene #1000000049), 122,411 In Vivo:Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: .. Chai et al. [ ] , ORL48, ORL115, ORL136, ORL150, ORL153, ORL156, ORL166, ORL174, ORL188, ORL195, ORL204, ORL207, ORL214, ORL215 , Human Improved Genome-wide Knockout CRISPR Library v1 (Addgene #67989), 90,709 Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: Goto et al. [ ] , CAL27 , Human kinome CRISPR pooled library (Brunello, RRID: Addgene_75312); Coverage: 650×; MOI: 0.3. , INK128 (10 nM) treatment until ~20 population doublings. Puromycin selection not specified , Treatment-Perturbed (mTOR inhibitor INK128 10 nM) , CDK4/6 signaling , - Identified synthetic lethality between mTOR and CDK4/6 signaling - Combination of INK128 and palbociclib leads to synergistic killing in vitro/in vivo - Mechanism: blocking eIF4G-CCNE1 complex formation. , N/A. .. Qiu et al. [ ] , SCC15 , Human GeCKO v2 CRISPR library (A + B sets, Addgene #1000000049), 122,411 Biomarker Discovery:Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: .. Chai et al. [ ] , ORL48, ORL115, ORL136, ORL150, ORL153, ORL156, ORL166, ORL174, ORL188, ORL195, ORL204, ORL207, ORL214, ORL215 , Human Improved Genome-wide Knockout CRISPR Library v1 (Addgene #67989), 90,709 Control:Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: Goto et al. [ ] , CAL27 , Human kinome CRISPR pooled library (Brunello, RRID: Addgene_75312); Coverage: 650×; MOI: 0.3. , INK128 (10 nM) treatment until ~20 population doublings. Puromycin selection not specified , Treatment-Perturbed (mTOR inhibitor INK128 10 nM) , CDK4/6 signaling , - Identified synthetic lethality between mTOR and CDK4/6 signaling - Combination of INK128 and palbociclib leads to synergistic killing in vitro/in vivo - Mechanism: blocking eIF4G-CCNE1 complex formation. , N/A. .. Qiu et al. [ ] , SCC15 , Human GeCKO v2 CRISPR library (A + B sets, Addgene #1000000049), 122,411 Infection:Article Title: Target Discovery in Head-and-Neck Squamous Cell Carcinoma: Genome-Wide CRISPR Screens Illuminate Therapeutic Resistance and Actionable Dependencies Article Snippet: Goto et al. [ ] , CAL27 , Human kinome CRISPR pooled library (Brunello, RRID: Addgene_75312); Coverage: 650×; MOI: 0.3. , INK128 (10 nM) treatment until ~20 population doublings. Puromycin selection not specified , Treatment-Perturbed (mTOR inhibitor INK128 10 nM) , CDK4/6 signaling , - Identified synthetic lethality between mTOR and CDK4/6 signaling - Combination of INK128 and palbociclib leads to synergistic killing in vitro/in vivo - Mechanism: blocking eIF4G-CCNE1 complex formation. , N/A. .. Qiu et al. [ ] , SCC15 , Human GeCKO v2 CRISPR library (A + B sets, Addgene #1000000049), 122,411 |